MK-571 sodium salt hydrate - CAS 115103-85-0
Catalog number: 115103-85-0
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Leukotriene Receptor
The sodium salt hydrate of MK-571 which is an effective antagonist of CysLT1 receptor and an inhibitor of MRP1.
Related CAS:
115104-28-4 (free acid)
Solid powder
sodium (E)-3-(((3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)((3-(dimethylamino)-3-oxopropyl)thio)methyl)thio)propanoate; MK-571; MK 571; MK571; MK-571 sodium salt; L-660,711; L660,711; L 660,711; L-660711; L660711; L 660711
DMSO: ≥ 33 mg/mL
-20ºC Freeze
The sodium salt hydrate of MK-571 which is an effective antagonist of CysLT1 receptor and an inhibitor of MRP1.
Shelf Life:
As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly
Canonical SMILES:
1.Uptake and metabolism of sulphated steroids by the blood-brain barrier in the adult male rat.
Qaiser MZ;Dolman DEM;Begley DJ;Abbott NJ;Cazacu-Davidescu M;Corol DI;Fry JP J Neurochem. 2017 Sep;142(5):672-685. doi: 10.1111/jnc.14117. Epub 2017 Aug 3.
Little is known about the origin of the neuroactive steroids dehydroepiandrosterone sulphate (DHEAS) and pregnenolone sulphate (PregS) in the brain or of their subsequent metabolism. Using rat brain perfusion in situ, we have found ;3; H-PregS to enter more rapidly than ;3; H-DHEAS and both to undergo extensive (> 50%) desulphation within 0.5 min of uptake. Enzyme activity for the steroid sulphatase catalysing this deconjugation was enriched in the capillary fraction of the blood-brain barrier and its mRNA expressed in cultures of rat brain endothelial cells and astrocytes. Although permeability measurements suggested a net efflux, addition of the efflux inhibitors GF120918 and/or MK571 to the perfusate reduced rather than enhanced the uptake of ;3; H-DHEAS and ;3; H-PregS; a further reduction was seen upon the addition of unlabelled steroid sulphate, suggesting a saturable uptake transporter. Analysis of brain fractions after 0.5 min perfusion with the ;3; H-steroid sulphates showed no further metabolism of PregS beyond the liberation of free steroid pregnenolone. By contrast, DHEAS underwent 17-hydroxylation to form androstenediol in both the steroid sulphate and the free steroid fractions, with some additional formation of androstenedione in the latter.
2.Bronchodilation with a potent and selective leukotriene D4 (LTD4) receptor antagonist (MK-571) in patients with asthma.
Gaddy JN;Margolskee DJ;Bush RK;Williams VC;Busse WW Am Rev Respir Dis. 1992 Aug;146(2):358-63.
The sulfidopeptide leukotrienes LTC4, LTD4, and LTE4 can cause airway smooth muscle contraction and have been implicated in the pathophysiology of asthma. MK-571 is a selective, potent LTD4 receptor antagonist that could attenuate airway obstruction in asthma by inhibiting the actions of sulfidopeptides at the LTD4 receptor site. The objectives of this study were to investigate the potential for MK-571 to cause bronchodilation in asthma patients with existing airway obstruction and to evaluate its effect on the bronchodilation response to an inhaled beta 2-agonist (albuterol). Twelve male patients (ages 19 to 42 yr) with asthma (baseline FEV1 50 to 80% predicted) participated in this placebo-controlled, randomized, two-period, cross-over study. On separate treatment days, each patient received either MK-571 or placebo intravenously for 6 h; inhaled albuterol was administered at the fifth and sixth hour of MK-571/placebo treatment to achieve maximal bronchodilation on that study day. Spirometry (forced expiratory volume in 1 s, FEV1) was monitored at intervals throughout each study period. MK-571 caused clinically significant bronchodilation; the increase in FEV1 above baseline, 20 min after the start of the MK-571 infusion, was 22 +/- 3.
3.Evaluation and comparison of MRP1 activity with three fluorescent dyes and three modulators in leukemic cell lines.
Dogan AL;Legrand O;Faussat AM;Perrot JY;Marie JP Leuk Res. 2004 Jun;28(6):619-22.
MRP1 activity was evaluated and compared in 11 cell lines with different levels of MRP1 expression using functional assays of calcein acetoxymethyl ester (calcein-AM), carboxyfluorescein diacetate (CFDA) and Rhodamine 123 (Rh123) in combination with the modulators cyclosporin A (CsA), probenecid and MK571. A good correlation was found between MRP1 expression and the modulatory effect of MK571 on calcein-AM uptake (P = 0.01 and probenecid effect on CFDA uptake (P = 0.02). Additionally, the combined modulatory effect of MK571 and probenecid on CFDA uptake (P < 0.0001) and on calcein-AM uptake (P = 0.0001) were highly significant. No correlation was found between MRP1 expression and the effects of three modulators on Rh123 uptake or efflux. In conclusion, calcein-AM and CFDA uptake assays are the best choices to probe MRP1 activity and combination of two modulators may improve the efficiency of these assays.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Leukotriene Receptor Products

(CAS: 1232861-58-3)

This active molecular is an potent dual Leukotriene CysLT1 and CysLT2 Receptor antagonist originated by Ono Pharmaceutical. IC50 values is 1.7nM against human C...

(CAS: 134002-60-1)

This active molecular is a selective LTD4 antagonist. CP-85958 may become a clinical candidates for the treatment of asthma in the future.

(CAS: 153227-04-4)

LY-306669, a tetrazol derivative, has been found to be a leukotriene B4 receptor antagonist that was once studied its effect in acute lung injury.

CAS 154355-76-7 Atreleuton

(CAS: 154355-76-7)

Atreleuton, a kind of urea compound, has been found to be a 5-lipoxygenase inhibitor as well as Leukotriene B4 receptor antagonist that could probably be useful...

(CAS: 169626-43-1)

WAY-126299A, a benzothiazoly derivative, has been found to be a 5-lipoxygenase inhibitor as well as Leukotriene D4 receptor antagonist and was once studied in A...

CAS 712313-35-4 HAMI3379

(CAS: 712313-35-4)

HAMI3379 is a cysteinyl leukotriene 2 (CysLT2) receptor antagonist. It can inhibit radioligand binding of LTD4 to CysLT2 and CysLT1 receptor cell lines with IC5...

LY 245769
(CAS: 127345-02-2)

LY 245769 is a leukotriene E4 (LTE4) inhibitor, and it can inhibit the oxidative degradation of LTE4 and N-acetyl-LTE4 in animal model. LY 245769, as one of the...

(CAS: 155944-23-3)

ZM-230487, a quinolin derivative, has been found to be a 5-lipoxygenase inhibitor as well as Leukotriene D4 receptor antagonist. It was once studied in anti-inf...

(CAS: 107889-31-6)

LY-25648 is a leukotriene B4 antagonist.

CAS 148291-65-0 LY 210073

LY 210073
(CAS: 148291-65-0)

LY 210073, an oxoxanthene derivative, has been found to be a LTB4 receptor antagonist that could probably be effective against inflammation and rheumatic disord...

CAS 40785-97-5 FPL 55712

FPL 55712
(CAS: 40785-97-5)

FPL 55712 is a leukotriene receptor antagonist that inhibits contraction of guinea pig trachealis induced by leukotrienes C4, D4, E4 and F4.

CP-199330 Sodium
(CAS: 158102-98-8)

The sodium salt form of CP-199330 which is a chromen derivative and has been found to be a Leukotriene D4 receptor antagonist that was once studied against asth...

CAS 151767-02-1 Montelukast Sodium

Montelukast Sodium
(CAS: 151767-02-1)

Montelukast is a leukotriene receptor antagonist (LTRA) used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies.

(CAS: 158081-99-3)

CP-105696, a chromen derivative, has been found to be a leukotriene B4 receptor antagonist that was once studied against sorts of nflammatory disease.

CAS 113806-05-6 Olopatadine

(CAS: 113806-05-6)

This active molecular is an antihistamine, anticholinergic and mast cell stabilizer. Olopatadine blocks the action of endogenous histamine. It is used to treat ...

LY 213024
(CAS: 117423-95-7)

LY 213024 is a potent leukotriene B4 receptor antagonist. Agents which block the production of the leukotrienes have shown reduction of infarct size in animal m...

CAS 146662-42-2 SR 2640 hydrochloride

SR 2640 hydrochloride
(CAS: 146662-42-2)

SR 2640 hydrochloride is a potent and selective competitive leukotriene D4 and E4 receptor antagonist. SR 2640 has been shown to inhibit LTD4- but not histamine...

CAS 120443-16-5 Verlukast

(CAS: 120443-16-5)

This active molecular is a R-enantiomer of MK-571 which is a selective LTD4 receptor antagonist. Verlukast showed [3H]leukotriene D4 binding in guinea-pig with ...

LY 203647
(CAS: 122009-61-4)

LY 203647 is a a leukotriene D4 and E4 receptor antagonist with a tetrazole nucleus structure originated by Eli Lilly. No development for treatment of Ischaemic...

CAS 117690-79-6 LY255283

(CAS: 117690-79-6)

This active molecular is a competitive leukotriene B4 receptor antagonist and IC50 value is about 100 nM. LY 255283 is selective for the BLT2 receptor, since IC...

Quick Inquiry

Verification code

Featured Items